13F-HR filed by Saturn V Capital Management LP
Saturn V Capital Management LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 20 holding rows worth $544,900,849.
- Accession
- 0001964437-26-000003
- Filer
- CIK 1964437
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 20 entries on the cover page, a total value of $544,900,849 stated on the cover page (in dollars after the unit check, H1), rows summing to $544,900,849 with VALUE read as dollars as filed, 13F file number 028-22863. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 649,179 | $87,545,034 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 4,496,487 | $54,317,563 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 1,217,064 | $43,230,113 | dollars as filed | |
| JAZZ PHARMACEUTICALS PLC SHS USD | G50871105 | Stock | 248,070 | $42,171,900 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 798,940 | $36,863,092 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 1,788,616 | $34,985,329 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 1,140,033 | $31,635,916 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 317,095 | $31,627,055 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 3,135,953 | $30,606,901 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 298,429 | $23,698,247 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 5,800,530 | $23,202,120 | dollars as filed | |
| MONOPAR THERAPEUTICS INC | 61023L207 | COMMON STOCK | 325,701 | $21,268,275 | dollars as filed | |
| INVIVYD INC | 00534A102 | COMMON STOCK | 7,735,386 | $19,106,403 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 1,504,880 | $18,269,243 | dollars as filed | |
| IMMIX BIOPHARMA INC | 45258H106 | COMMON STOCK | 2,999,169 | $15,685,654 | dollars as filed | |
| OCULIS HOLDING AG | H5870P102 | CMN | 516,761 | $10,319,717 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 3,856,799 | $7,906,438 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 282,692 | $7,070,127 | dollars as filed | |
| OVID THERAPEUTICS INC | 690469101 | COMMON STOCK | 2,500,000 | $4,075,000 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 283,166 | $1,316,722 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001964437-26-000003 | this filing | 2026-02-17 | acceptance time not in the bulk data set |